Navigation Links
United States Seizes Unapproved Ozone Generators

FDA inspection shows devices produced under poor manufacturing condition; pose public health risk

SILVER SPRING, Md., Jan. 29 /PRNewswire-USNewswire/ -- At the request of the U.S. Food and Drug Administration, U.S. Marshals today seized 77 ozone generators, models AOS-1M and AOS-1MD, from Applied Ozone Systems of Auburn, Calif. The seized goods, which are medical devices, are valued at $75,900.


The FDA advises health care professionals and consumers to discontinue use of these devices, which Applied Ozone Systems claims can treat cancer, AIDS, hepatitis, herpes, and a number of other diseases and conditions. The FDA has not determined that the seized products are safe and effective in treating the diseases or conditions, and officials at Applied Ozone Systems never responded to a Dec. 21, 2009 FDA request for a voluntary recall of these ozone generators.

In addition, the agency is concerned that patients who use these AOS ozone devices as directed by the manufacturer may believe that ozone therapy serves as an appropriate treatment and as a result delay or stop conventional or prescribed effective treatment. There is also a risk of infection from potential contamination of the applicator or catheter.

The FDA inspected Applied Ozone Systems in October 2009 after obtaining an inspection warrant when the owner of the company refused to allow agency staff to inspect the facility. The agency's inspection revealed significant deviations from the FDA's current good manufacturing practice (GMP) requirements for medical devices, and confirmed that the company has not obtained FDA marketing approval or clearance for these devices. The unapproved status of these devices and the conditions under which they were manufactured cause them to be adulterated and misbranded.

Ozone generators are devices that produce ozone from oxygen. Ozone is present in low levels throughout the earth's atmosphere and has many industrial and consumer applications. It also is an air pollutant that has harmful effects on the respiratory system.

Ozone administration methods suggested by the manufacturer of the AOS-1M Medical Ozone Generator and the AOS-1MD Ozone Generator include blowing ozonized air into the rectal and vaginal areas.

"The seized devices are potentially harmful to public health," said Michael Chappell, the FDA's acting associate commissioner for regulatory affairs. "The agency will take action to protect the public from FDA-regulated products that are in violation of the law."

Today's seizure action was jointly conducted by the FDA and the State of California Department of Public Health, Food and Drug Branch as part of ongoing to efforts to ensure that unapproved medical devices that have not been found to be safe and effective do not enter the marketplace.

Health care professionals and consumers may report serious adverse events (side effects) or product quality problems with the use of these products to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail, fax or phone.

Media Inquiries: Tom Gasparoli, 301-796-4737,

Consumer Inquiries: 888-INFO-FDA

SOURCE U.S. Food and Drug Administration



SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
2. R-CALF United Stockgrowers of America: Fighting for the U.S. Cattle Producer
3. United States, Canada and Mexico Agree to Mutual Assistance During Public Health Emergencies
4. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
5. Peptimmune Announces Grant of United States Patent for PI-2301 Peptide Copolymer for Multiple Sclerosis
6. A First-Line Therapy for Renal Cell Carcinoma that can Increase Overall Survival when Compared with Sutent Would Earn a Higher Patient Share in the United States Than in Europe
7. American Oriental Bioengineering to Initiate a Phase One Clinical Trial in the United States of AOBO-001 Oral Capsule
8. Premier Research Expands its Medical Device Operations to the United States
9. Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)
10. United States Patent and Trademark Office Publishes Stemedicas Patent Application for the Treatment of Diabetic Retinopathy
11. EMD Serono Submits Application for Cladribine Tablets as a Potential Oral Short-Course Multiple Sclerosis Therapy in the United States
Post Your Comments:
(Date:12/1/2015)... Calif. , Dec. 1, 2015  Avanir ... prevalence of symptoms for pseudobulbar affect (PBA), a ... of laughing and/or crying resulting from certain neurologic ... of antipsychotic medications in nursing home residents, were ... Psychiatry. The study showed that almost one in ...
(Date:12/1/2015)... December 1, 2015 Biovicas ... Study Group (IBCSG, Bern ) ... i en klinisk studie av palbociclib, ett nytt ... --> Studien, med namn PYTHIA, kommer följa ... läkemedel i kombination med palbociclib, som tillhör klassen ...
(Date:11/30/2015)... 1, 2015 Express Scripts (NASDAQ: ESRX ) ... IMMY ) to drive access to a low-cost alternative to ... toxoplasmosis that has been recently priced out of reach for ... systems. --> --> Imprimis ... (a form of folic acid) for $1 per capsule for people ...
Breaking Medicine Technology:
(Date:12/1/2015)... PITTSBURGH, PA (PRWEB) , ... December 01, 2015 ... ... or imaging facilities, radiographic technicians must mark the film for accurate interpretation by ... keep track of. Fortunately, an inventor from Sacramento, Calif., has found a way ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... it has been selected as a finalist in this year’s Fierce Innovation Awards: ... Next IT Healthcare was recognized as a finalist in the category of Digital ...
(Date:12/1/2015)... ... December 01, 2015 , ... PYA’s latest white paper, ... addresses a main “pain point” for merging or aligning healthcare provider organizations—when mergers ... is signed. This quick-read guidance suggests that failing to recognize the power ...
(Date:12/1/2015)... ... 01, 2015 , ... Nurotron Biotechnology Co., Ltd., maker of cochlear implant systems, ... , The order will be from the China Disabled Persons’ Federation, a central government ... effective solution for children and adults suffering from severe and profound hearing loss ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... companies, announced today that it has officially launched a sleek, mobile-ready and user-centric ... that his company’s new website clearly outlines the benefits that its SEO services ...
Breaking Medicine News(10 mins):